Vera Therapeutics (NASDAQ:VERA) Shares Climb 5.4% – Here’s What Happened

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) shot up 5.4% during trading on Thursday. The company traded as high as $26.88 and last traded at $26.9550. Approximately 448,620 shares changed hands during trading, a decline of 72% from the average session volume of 1,606,382 shares. The stock had previously closed at $25.58.

Analyst Ratings Changes

Several brokerages recently issued reports on VERA. JPMorgan Chase & Co. lifted their price objective on Vera Therapeutics from $76.00 to $83.00 and gave the stock an “overweight” rating in a report on Tuesday, September 8th. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, September 15th. Wall Street Zen raised Vera Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 7th. Guggenheim dropped their price target on Vera Therapeutics from $76.00 to $66.00 and set a “buy” rating for the company in a research report on Friday, November 6th. Finally, Wedbush reduced their price objective on Vera Therapeutics from $34.00 to $29.00 and set a “neutral” rating on the stock in a research report on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Vera Therapeutics has an average rating of “Moderate Buy” and an average price target of $74.93.

View Our Latest Analysis on VERA

Vera Therapeutics Trading Up 4.9%

The company has a quick ratio of 7.78, a current ratio of 7.91 and a debt-to-equity ratio of 0.23. The firm has a market cap of $1.94 billion, a price-to-earnings ratio of -4.53 and a beta of 1.07. The business has a 50 day moving average price of $30.58 and a 200-day moving average price of $35.97.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.30) EPS for the quarter, topping analysts’ consensus estimates of ($1.62) by $0.32. The firm had revenue of $10.28 million during the quarter, compared to analyst estimates of $3.42 million. As a group, research analysts expect that Vera Therapeutics, Inc. will post -6.00 EPS for the current fiscal year.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $37.00, for a total value of $684,500.00. Following the sale, the chief executive officer directly owned 235,244 shares in the company, valued at approximately $8,704,028. This trade represents a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

Several hedge funds have recently modified their holdings of the company. Eurizon Capital SGR S.p.A. bought a new stake in shares of Vera Therapeutics during the 3rd quarter worth $32,000. Allworth Financial LP boosted its position in shares of Vera Therapeutics by 66.3% in the 3rd quarter. Allworth Financial LP now owns 1,515 shares of the company’s stock valued at $49,000 after purchasing an additional 604 shares during the period. Steward Partners Investment Advisory LLC increased its stake in Vera Therapeutics by 110.4% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 2,045 shares of the company’s stock worth $66,000 after purchasing an additional 1,073 shares in the last quarter. Sterling Capital Management LLC raised its holdings in Vera Therapeutics by 841.5% during the 3rd quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $68,000 after buying an additional 1,885 shares during the period. Finally, Fulcrum Asset Management LLP acquired a new stake in Vera Therapeutics during the 3rd quarter worth about $74,000. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Vera Therapeutics Company Profile

(Get Free Report)

Vera Therapeutics is a clinical-stage biotechnology company developing treatments for immune-mediated diseases. Headquartered in Brisbane, California, the company focuses on therapies intended to address underlying immune processes involved in conditions with significant unmet medical needs. Its lead investigational candidate, atacicept, is a fusion protein designed to inhibit BAFF and APRIL, proteins that support B-cell activity and antibody production. Vera is studying atacicept for IgA nephropathy and other autoimmune diseases.

Read More

Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.